вторник, 31 мая 2016 г.

Investment Analysts' Recent Ratings Changes for Teva Pharmaceutical Industries

Investment Analysts' Recent Ratings Changes for Teva Pharmaceutical Industries


According to Zacks, "Although Teva's first quarter 2016 results were better-than-expected, headwinds remain for the company in the form of generic competition for Copaxone, as well as new competition for branded products. Meanwhile, the generics segment could remain under pressure in the absence of important new product launches.



from Biotech News